XML 33 R19.htm IDEA: XBRL DOCUMENT
v3.24.1

INCOME TAXES | 12 Months Ended
--- | ---
Dec. 31, 2023
Income Tax Disclosure [Abstract] |
INCOME TAXES | NOTE 13 – INCOME TAXES The Company accounts for income taxes in accordance with ASC Topic No. 740, Income Taxes. This standard requires the Company to provide a net deferred tax asset or liability equal to the expected future tax benefit or expense of temporary reporting differences between book and tax accounting and any available operating loss or tax credit carry forwards. As discussed in Notes 3 and 4, the Company recognized net deferred tax liabilities associated with the Precision Healing merger and the Scendia acquisition. As of the dates of these acquisitions, prior to consideration of these acquired deferred tax liabilities, the Company had net deferred tax assets in excess of the deferred tax liabilities being recognized, however, a 100% valuation allowance had previously been provided against the Company’s net deferred tax assets. As a result of the recording of the net deferred tax liabilities related to the Precision Healing merger and Scendia acquisition, the Company reviewed the valuation allowance and determined that it should be reduced by the amount of the deferred tax liabilities that were recognized. This resulted in a year-to-date income tax benefit of $5.8 million for the year ending December 31, 2022. After applying the provisions of Section 382 of the Internal Revenue Code, the unexpired net operating loss (“NOL”) carryforward at December 31, 2023 was approximately $55.7 million, of which, approximately $27.0 million, generated in 2017 and prior, will expire between 2024 and 2037. Under the Tax Cuts and Jobs Act, the NOL generated from 2018 through 2023, of approximately $28.7 million, will have an indefinite carryforward period but can generally only be used to offset 80% of taxable income in any particular year. The Company may be subject to certain limitations in its annual utilization of NOL carry forwards to off-set future taxable income pursuant to Section 382 of the Internal Revenue Code, which could result in NOLs expiring unused. The components of the deferred income tax assets and liabilities consisted of the following: SCHEDULE OF DEFERRED TAX ASSETS
|  | 2023 |  |  | 2022 |
|  | As of December 31, |
|  | 2023 |  |  | 2022 |
Deferred tax assets |  |  |  |  |  |  |  |
Net operating loss carry forwards |  | $ | 12,467,570 |  |  | $ | 6,818,547 |
Research and development costs |  |  | 2,119,193 |  |  |  | 707,076 |
Stock compensation expense |  |  | 711,598 |  |  |  | 232,250 |
Accrued expenses |  |  | 528,148 |  |  |  | - |
Lease liability |  |  | 512,668 |  |  |  | - |
Contingent liability |  |  | 221,028 |  |  |  | - |
Acquisition liability |  |  | 176,629 |  |  |  | - |
Bad debt and other reserves |  |  | 129,924 |  |  |  | 92,286 |
Inventory reserves |  |  | 109,176 |  |  |  | 43,678 |
Other temporary differences |  |  | 203,340 |  |  |  | 26,102 |
Total deferred tax assets |  |  | 17,179,274 |  |  |  | 7,919,939 |
Deferred tax liabilities |  |  |  |  |  |  |  |
Depreciation and amortization |  |  | (6,180,688 | ) |  |  | (5,919,626 | )
Right of Use assets |  |  | (487,402 | ) |  |  | - |
Accrued expenses |  |  | (424,423 | ) |  |  | (26,903 | )
Contingent liability |  |  | (130,802 | ) |  |  | - |
Other temporary differences |  |  | (166,712 | ) |  |  | - |
Valuation allowance |  |  | (9,789,247 | ) |  |  | (1,973,410 | )
Net deferred tax asset |  | $ | - |  |  | $ | - |
A 100% valuation allowance has been provided for all deferred tax assets, as the ability of the Company to generate sufficient taxable income in the future is uncertain. Reconciliations of the expected federal income tax benefit based on the statutory income tax rate of 21% to the actual benefit for the years ended December 31, 2023 and 2022 are listed below. SCHEDULE OF INCOME TAX EXPENSE (BENEFIT)
|  | 2023 |  |  | 2022 |
|  | For the Year Ended December 31, |
|  | 2023 |  |  | 2022 |
Expected federal income tax (expense) benefit |  | $ | (903,220 | ) |  | $ | 2,851,758 |
State and local taxes, net of federal (expense) benefit |  |  | (226,714 | ) |  |  | - |
Fair value adjustments |  |  | (819,270 | ) |  |  | - |
Share-based compensation |  |  | (557,168 | ) |  |  | (249,516 | )
Other permanent differences |  |  | 118,765 |  |  |  | - |
NOL carryover adjusted for expiration |  |  | - |  |  |  | 46,936 |
Equity method investment loss |  |  | - |  |  |  | (79,723 | )
Meals and entertainment |  |  | - |  |  |  | (4,843 | )
Research and development costs |  |  | - |  |  |  | (707,076 | )
Other temporary differences |  |  | - |  |  |  | 329,829 |
NOL carryover adjustments |  |  | (5,148,128 | ) |  |  | - |
Intangibles |  |  | (720,407 | ) |  |  | - |
Other true ups |  |  | (230,474 | ) |  |  | - |
Changes in tax rates |  |  | 673,449 |  |  |  | - |
Change in valuation allowance |  |  | 7,813,167 |  |  |  | 3,657,431 |
Income tax (expense) benefit |  | $ | - |  |  | $ | 5,844,796 |
All tax years starting with 2021 are open for examination.

X
- References No definition available. + Details
Name: | us-gaap_IncomeTaxDisclosureAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480990/946-20-50-13 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(h)(2)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//740/tableOfContent Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482685/740-10-50-14 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482685/740-10-50-21 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 270 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482526/740-270-50-1 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 17 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB TOPIC 6.I.5.Q1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 11.C) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-2 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482603/740-30-50-2 + Details
Name: | us-gaap_IncomeTaxDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration